Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 150.85
ARWR's Cash to Debt is ranked higher than
75% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. ARWR: 150.85 )
ARWR' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 150.85

Equity to Asset 0.91
ARWR's Equity to Asset is ranked higher than
93% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ARWR: 0.91 )
ARWR' s 10-Year Equity to Asset Range
Min: -32.54   Max: 0.91
Current: 0.91

-32.54
0.91
F-Score: 4
Z-Score: 10.96
M-Score: -4.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -30269.89
ARWR's Operating margin (%) is ranked lower than
52% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. ARWR: -30269.89 )
ARWR' s 10-Year Operating margin (%) Range
Min: -70800   Max: -40
Current: -30269.89

-70800
-40
Net-margin (%) -33312.50
ARWR's Net-margin (%) is ranked lower than
51% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. ARWR: -33312.50 )
ARWR' s 10-Year Net-margin (%) Range
Min: -33502.86   Max: 1602.7
Current: -33312.5

-33502.86
1602.7
ROE (%) -44.79
ARWR's ROE (%) is ranked higher than
71% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. ARWR: -44.79 )
ARWR' s 10-Year ROE (%) Range
Min: -225.02   Max: -28.66
Current: -44.79

-225.02
-28.66
ROA (%) -41.17
ARWR's ROA (%) is ranked higher than
68% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. ARWR: -41.17 )
ARWR' s 10-Year ROA (%) Range
Min: -447.27   Max: 705.95
Current: -41.17

-447.27
705.95
ROC (Joel Greenblatt) (%) -1519.02
ARWR's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. ARWR: -1519.02 )
ARWR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -11843.37   Max: -75
Current: -1519.02

-11843.37
-75
Revenue Growth (3Y)(%) -100.00
ARWR's Revenue Growth (3Y)(%) is ranked higher than
53% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. ARWR: -100.00 )
ARWR' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 63.5
Current: -100

0
63.5
EBITDA Growth (3Y)(%) -5.80
ARWR's EBITDA Growth (3Y)(%) is ranked higher than
76% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. ARWR: -5.80 )
ARWR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -56.3   Max: 190.5
Current: -5.8

-56.3
190.5
EPS Growth (3Y)(%) 1.90
ARWR's EPS Growth (3Y)(%) is ranked higher than
81% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. ARWR: 1.90 )
ARWR' s 10-Year EPS Growth (3Y)(%) Range
Min: -75.1   Max: 162.1
Current: 1.9

-75.1
162.1
» ARWR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ARWR Guru Trades in

Q4 2013

ARWR Guru Trades in Q4 2013

Steven Cohen 1,500,000 sh (New)
Jim Simons 54,400 sh (New)
» More
Q1 2014

ARWR Guru Trades in Q1 2014

George Soros 44,200 sh (New)
Steven Cohen 2,740,000 sh (+82.67%)
Jim Simons Sold Out
» More
Q2 2014

ARWR Guru Trades in Q2 2014

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ARWR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Sold Out 0.01%$9.79 - $18.28 $ 6.35-52%0
George Soros 2014-03-31 New Buy0.01%$9.92 - $26.57 $ 6.35-63%44200
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.20
ARWR's P/B is ranked higher than
90% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. ARWR: 2.20 )
ARWR' s 10-Year P/B Range
Min: 0.06   Max: 75.56
Current: 2.2

0.06
75.56
EV-to-EBIT -3.63
ARWR's EV-to-EBIT is ranked higher than
71% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ARWR: -3.63 )
ARWR' s 10-Year EV-to-EBIT Range
Min: -294.1   Max: -0.3
Current: -3.63

-294.1
-0.3
Current Ratio 13.07
ARWR's Current Ratio is ranked higher than
91% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. ARWR: 13.07 )
ARWR' s 10-Year Current Ratio Range
Min: 0.01   Max: 22.28
Current: 13.07

0.01
22.28
Quick Ratio 13.07
ARWR's Quick Ratio is ranked higher than
91% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. ARWR: 13.07 )
ARWR' s 10-Year Quick Ratio Range
Min: 0.01   Max: 22.28
Current: 13.07

0.01
22.28

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.52
ARWR's Price/Net Cash is ranked higher than
96% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 53.79 vs. ARWR: 2.52 )
ARWR' s 10-Year Price/Net Cash Range
Min: 0.05   Max: 21.43
Current: 2.52

0.05
21.43
Price/Net Current Asset Value 2.52
ARWR's Price/Net Current Asset Value is ranked higher than
96% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 31.40 vs. ARWR: 2.52 )
ARWR' s 10-Year Price/Net Current Asset Value Range
Min: 0.05   Max: 21
Current: 2.52

0.05
21
Price/Tangible Book 2.10
ARWR's Price/Tangible Book is ranked higher than
93% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9.45 vs. ARWR: 2.10 )
ARWR' s 10-Year Price/Tangible Book Range
Min: 0.04   Max: 15.11
Current: 2.1

0.04
15.11
Price/DCF (Projected) 211.67
ARWR's Price/DCF (Projected) is ranked higher than
90% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ARWR: 211.67 )
ARWR' s 10-Year Price/DCF (Projected) Range
Min: 166.11   Max: 501.67
Current: 211.67

166.11
501.67
Earnings Yield (Greenblatt) -26.70
ARWR's Earnings Yield (Greenblatt) is ranked higher than
56% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. ARWR: -26.70 )
ARWR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -26.7

Analyst Estimate

Sep15 Sep16 Sep17
Revenue(Mil) 0 0
EPS($) -1.17 -1.69 -1.70
EPS without NRI($) -1.17 -1.69 -1.70

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HDP1.Germany,
Arrowhead Research Corp was originally incorporated in South Dakota in 1989, and was reincorporated in Delaware in 2000. It is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary drug delivery technologies to develop drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Its pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology. The product include ARC-520, Adipotide, CRLX-101, Tubulin Inhibitor.The drug products are regulated by FDA under the Federal Food, Drug and Cosmetic Act (the "FDCA"), and other laws within the Public Health Service Act.
» More Articles for ARWR

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: NRP, OPK, GAM, KEY, ARWR Oct 20 2014 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 10 2011 
Weekly CFO Buys Highlight: JAZZ, VRTB, ASTM, ARWR, CGX Sep 04 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 13 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 11 2010 
Arrowhead Research Corp. Reports Operating Results (10-K) Dec 22 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Aug 10 2009 
Arrowhead Reports Third Quarter Fiscal 2009 Financial Results Aug 10 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 15 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 09 2009 

More From Other Websites
Arrowhead Files IND for RNAi Therapeutic ARC-520 to Begin Phase 2b Multiple-Dose Studies in Chronic... Dec 15 2014
ARROWHEAD 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General... Dec 05 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in... Dec 05 2014
Arrowhead Appoints Patrick O’Brien as General Counsel Dec 04 2014
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against... Dec 03 2014
ARROWHEAD RESEARCH CORP Financials Dec 02 2014
INVESTOR ALERT: Class Action Lawsuit Against Arrowhead Research Corporation Announced by Law Offices... Dec 01 2014
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Arrowhead... Dec 01 2014
ARROWHEAD RESEARCH CORP. SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti,... Nov 28 2014
10-K for Arrowhead Research Corp. Nov 27 2014
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the... Nov 26 2014
Arrowhead Research misses 4Q profit forecasts Nov 25 2014
Arrowhead Reports Fiscal 2014 Year End Financial Results Nov 25 2014
ARROWHEAD RESEARCH CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 25 2014
Q4 2014 Arrowhead Research Corp Earnings Release - After Market Close Nov 25 2014
EQUITY ALERT: Rosen Law Firm Reminds Arrowhead Research Corp. Investors of Important December 9,... Nov 24 2014
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Arrowhead... Nov 24 2014
SHAREHOLDER ALERT: Investigation on Behalf of Arrowhead Research Corporation Investors Announced by... Nov 21 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Arrowhead... Nov 21 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Nov 19 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK